BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
After Change Up Top, Syntonix Inks Boehringer Ingelheim Deal Worth Up to $63M
News | 10. 24. 2005
Syntonix Pharmaceuticals
After a management change over the summer, drug formulation and delivery company Syntonix Pharmaceuticals Inc. has kicked off autumn with a collaboration with Boehringer Ingelheim GmbH that could bring in as much as $63 million.
